{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:46:21Z","timestamp":1783129581975,"version":"3.54.6"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.dmd.2025.100117","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:13:09Z","timestamp":1751422389000},"page":"100117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of various experimental conditions and mechanistic static versus dynamic models to predict time-dependent CYP3A4\/5 inhibition potential of drugs"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5385-0223","authenticated-orcid":false,"given":"Bad\u00e9e","family":"Justine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu","family":"Helen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-4394","authenticated-orcid":false,"given":"Huth","family":"Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poller","family":"Birk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-3985","authenticated-orcid":false,"given":"Schiller","family":"Hilmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenal","family":"Ga\u00eblle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Streckfuss","family":"Judith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birlinger","family":"Bertrand-Luc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshmukh","family":"Sujal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einolf J.","family":"Heidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.dmd.2025.100117_bib1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1851","article-title":"Predicting in vitro drug interactions from in vitro drug discovery data","volume":"4","author":"Wienkers","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.dmd.2025.100117_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.dmd.2025.100117_bib3","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2025.100117_bib4","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1124\/dmd.110.037911","article-title":"CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs","volume":"39","author":"Zimmerlin","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2025.100117_bib5","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2025.100117_bib6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2174\/156802611794480882","article-title":"Assessment of cytochrome P450 enzyme inhibition and inactivation in drug discovery and development","volume":"11","author":"Nettleton","year":"2011","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"10.1016\/j.dmd.2025.100117_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/17425255.2014.856882","article-title":"Exploring concepts of in vitro time-dependent CYP inhibition assays","volume":"10","author":"Stresser","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmd.2025.100117_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.708299","article-title":"Reviewing data integrated for PBPK model development to predict metabolic drug-drug interactions: shifting perspectives and emerging trends","volume":"12","author":"Abouir","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100117_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1124\/dmd.124.001660","article-title":"Drug interactions for P450 time-dependent inhibitors","volume":"52","author":"Tseng","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2025.100117_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2013.187","article-title":"Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin Pharm Ther"},{"issue":"7","key":"10.1016\/j.dmd.2025.100117_bib12","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3390\/ijms18071553","article-title":"Inhibitory effects of trapping agents of sulfur drug reactive intermediates against major human cytochrome P450 isoforms","volume":"18","author":"Sodhi","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.dmd.2025.100117_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/dmd.110.036400","article-title":"Prediction of CYP3A mediated drug-drug interactions using human hepatocytes suspended in human plasma","volume":"39","author":"Mao","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2025.100117_bib14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/dmd.111.043158","article-title":"Prediction of cytochromes P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation","volume":"40","author":"Mao","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2025.100117_bib15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/0091270003259216","article-title":"Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone","volume":"43","author":"Lam","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100117_bib16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00280-011-1585-0","article-title":"Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I\/II pharmacokinetic interaction study","volume":"68","author":"Flaherty","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100117_bib17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/bcp.15544","article-title":"Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours","volume":"89","author":"Chen","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100117_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5414\/CPP48103","article-title":"Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration","volume":"48","author":"Kovarik","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2025.100117_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/jcph.7","article-title":"A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects","volume":"53","author":"Urva","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100117_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jcph.434","article-title":"Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam","volume":"55","author":"Zhang","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100117_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cpt.1950","article-title":"Ribociclib drug-drug interactions: clinical evaluations and physiologically-based pharmacokinetic modeling to guide drug labeling","volume":"108","author":"Samant","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2025.100117_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00280-020-04180-3","article-title":"Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors","volume":"87","author":"Hurtado","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100117_bib23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2025.100117_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0091270005284854","article-title":"Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohost product to rifampicin and clarithromycin","volume":"46","author":"Gurley","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100117_bib25","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00228-013-1530-8","article-title":"Concentrations effect relationship of CYP3A4 inhibition by ritonavir in humans","volume":"69","author":"Eichbaum","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100117_bib26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0091270003256687","article-title":"Effect of mibefradil on CYP3A4 in vivo","volume":"43","author":"Veronese","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100117_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/jcph.79","article-title":"Time-dependent inhibition and induction of human cytochrome P4503A4\/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects","volume":"53","author":"Dhuria","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100117_bib28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1124\/dmd.111.039297","article-title":"Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes","volume":"40","author":"Kimoto","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2025.100117_bib29","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/j.xphs.2017.03.025","article-title":"Current in vitro methods to determine hepatic Kpuu: a comparison of their usefulness and limitations","volume":"106","author":"Riede","year":"2017","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.dmd.2025.100117_bib30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2025.100117_bib31","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/mp4000822","article-title":"Rapid measurement of intracellular unbound drug concentrations","volume":"10","author":"Mateus","year":"2013","journal-title":"Mol Pharmaceutics"},{"issue":"2","key":"10.1016\/j.dmd.2025.100117_bib32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the predictions of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100117_bib33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover","volume":"43","author":"Rowland","year":"2011","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100117_bib34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/clpt.2013.170","article-title":"Evaluation of various static and dynamic modeling methods to predict clinical CYP3a induction using in vitro CYP3A4 mRNA induction data","volume":"95","author":"Einolf","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2025.100117_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"issue":"7","key":"10.1016\/j.dmd.2025.100117_bib36","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"},{"issue":"4","key":"10.1016\/j.dmd.2025.100117_bib37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discov Today Technol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100117_bib38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.106.013359","article-title":"Misuse of the well-stirred model of hepatic drug clearance","volume":"35","author":"Yang","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2025.100117_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/psp4.12502","article-title":"Model-informed drug development for everolimus dosing selection in pediatric infant patients","volume":"9","author":"Combes","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100117_bib40","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.xphs.2019.01.028","article-title":"Physiologically based pharmacokinetic modeling to supplement nilotinib pharmacokinetics and confirm dose selection in pediatric patients","volume":"108","author":"Heimbach","year":"2019","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100117_bib41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Disp"},{"issue":"9","key":"10.1016\/j.dmd.2025.100117_bib42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0090-9556(24)15182-3","article-title":"An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation","volume":"28","author":"Mayhew","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2025.100117_bib43","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.dmd.2025.100117_bib44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1124\/dmd.121.000718","article-title":"Predictive in vitro-in vivo extrapolation for time dependent inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 using pooled human hepatocytes, human liver microsomes, and a simple mechanistic static model","volume":"50","author":"Ramsden","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2025.100117_bib45","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1038\/s41598-019-42051-x","article-title":"Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations","volume":"9","author":"Filppula","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.dmd.2025.100117_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107449","article-title":"Time-dependent enzyme inactivation: numerical analysis of in vitro data and prediction of drug-drug interactions","volume":"206","author":"Yadav","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmd.2025.100117_bib47","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/dmd.114.058289","article-title":"A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theorical considerations","volume":"42","author":"Nagar","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2025.100117_bib48","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.114.058297","article-title":"A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. Application to experimental data","volume":"42","author":"Korzekwa","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2025.100117_bib49","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1021\/acs.molpharmaceut.8b00129","article-title":"Improve predictions of drug-drug interactions mediated by time-dependent inhibition by CYP3A","volume":"15","author":"Yadav","year":"2018","journal-title":"Mol Pharm"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:13:31Z","timestamp":1756289611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0090955625091263"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100117","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of various experimental conditions and mechanistic static versus dynamic models to predict time-dependent CYP3A4\/5 inhibition potential of drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100117"}}